Non-alcoholic fatty liver disease increases cardiovascular and mortality risk in patients with diabetes
1. The risk of cardiovascular disease (CVD) and all-cause death for individuals with type 2 diabetes mellitus (T2DM) is increased ...
Tag: hepatology
Resmetirom improves liver fibrosis in nonalcoholic steatohepatitis
1. In this randomized controlled trial, among patients with nonalcoholic steatohepatitis (NASH) with liver fibrosis, resmetirom was superior to placebo ...
Zinc supplementation may improve metabolic outcomes in patients with non-alcoholic fatty liver disease
1. Patients randomized to have Zinc (Zn) supplementation incorporated into an 8-week diet and exercise intervention for patients with NAFLD ...
Higher intensity exercise associated with greater decrease in nonalcoholic fatty liver disease risk
1. This analysis of a population-based cohort found that those who engaged in high and moderate decreasing amounts of vigorous ...
2 Minute Medicine Rewind October 23, 2023
Noninvasive Bioelectronic Treatment of Postcesarean Pain: A Randomized Trial 1. In this randomized, sham-controlled clinical trial, the use of Transcutaneous ...
Camrelizumab plus rivoceranib superior to sorafenib for treatment of unresectable hepatocellular carcinoma
1. Patients in the camrelizumab-rivoceranib group reported significantly greater progression-free survival than the sorafenib group. 2. Treatment-related deaths were comparable ...
Younger onset of non-alcoholic fatty liver disease associated with greater cancer risk
1. In this case-control study, younger age of onset of non-alcoholic fatty liver disease (NAFLD) was associated with greater cancer ...
Pilot program of chronic hepatitis B treatment in Ethiopia
1. In this pilot program conducted in Ethiopia, researchers demonstrated the long-term benefits and feasibility of treatment for chronic hepatitis ...
2 Minute Medicine Rewind October 2, 2023
Exposure to Neighborhood Walkability and Residential Greenness and Incident Fracture 1. In this longitudinal cohort study, neighborhood walkability and greenness ...
Pegozafermin associated with improved outcomes in nonalcoholic steatohepatitis
1. In this randomized controlled trial, treatment with pegozafermin improved fibrosis in patients with nonalcoholic steatohepatitis (NASH). 2. Treatment with ...
